Calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukaemia
Less than 1% of patients treated with Calquence discontinued treatment due to cardiac adverse events in pooled analysisA pooled analysis of cardiovascular (CV) safety data from 762 patients treated with Calquence (acalabrutinib) monotherapy for chronic lymphocytic leukaemia (CLL), the most common type of adult leukaemia, across four clinical trials showed a low incidence of cardiac adverse events (AEs) leading to discontinuation.[1,2] These results were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on 7 December 2020. The analysis included